Shionogi Acquires RADICAVA Rights in $2.5B Deal to Expand Rare Disease Portfolio
Shionogi plans to acquire global rights to Tanabe Pharma's RADICAVA (edaravone), a drug for ALS, to strengthen its presence in rare diseases and expand its rare disease portfolio, including establishing a strong U.S. commercial platform with a $2.5 billion investment.